OPK OPKO Health Inc.

OPKO Health Appoints Dr. Roger Medel to its Board of Directors

OPKO Health Appoints Dr. Roger Medel to its Board of Directors

MIAMI, Dec. 21, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Roger Medel, M.D. as an independent member of its Board of Directors, effective December 18, 2020. With this appointment, the OPKO Health Board has 11 Directors, including seven independent Directors.

“We are delighted to welcome Roger to the OPKO Health Board of Directors,” stated Dr. Phillip Frost, Chairman and Chief Executive Officer of OPKO Health. “Roger brings a unique perspective based on his vast experience as a physician and as an executive growing a successful healthcare services organization. We look forward to Roger’s valuable insight and deep knowledge as we continue to execute OPKO’s strategy.”

Dr. Medel is the co-founder of MEDNAX, Inc., a national health solutions partner comprised of the nation’s leading providers of physician services, and has served as a Director of MEDNAX since 1979. In addition, he served as MEDNAX’s President from its founding until May 2000, then again from March 2003 until May 2004, and as its Chief Executive Officer since its founding until December 2002 then again from March 2003 until his retirement in July 2020. Under his leadership, the company grew from one small group of neonatologists managing care in one local hospital, to a group of more than 1,200 neonatologists and more than 1,000 advanced practice nurses that manages neonatology departments, including neonatal intensive care units in approximately 400 hospitals. Additionally, MEDNAX expanded into the largest group of pediatric cardiologists, pediatric intensivists and maternal fetal specialists. The company currently cares for approximately 25% of the sick and premature babies born annually in the United States.

Dr. Medel has served as a member of the Board of Trustees of the Dana Farber Cancer Institute, Inc. since January 2016. In addition, he was a member of the Board of Trustees of the University of Miami from January 2004 to February 2012, and from June 2006 to April 2009 served on the Board of Directors of MBF Healthcare Acquisition Corp. Dr. Medel actively participates as a member of several medical and professional organizations.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit .

Contacts:

LHA Investor Relations

Yvonne Briggs, 310-691-7100



or

Bruce Voss, 310-691-7100



EN
21/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OPKO Health Inc.

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: September 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Opko Health Inc: 1 director

A director at Opko Health Inc bought 675,000 shares at 1.320USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

OPKO Health Reports Second Quarter 2025 Business Highlights and Financ...

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 h...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch